Gamma-glutamyl transferase and risk of type II diabetes: An updated systematic review and dose-response meta-analysis

Annals of Epidemiology

Volumn 24, Issue 11, 2014, Pages 809-816

  Kunutsor, Setor K ^a   Abbasi, Ali ^b,c   Adler, Amanda I ^d  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

Dose response; Gamma glutamyl transferase; Meta analysis; Prospective studies; Type II diabetes mellitus

Indexed keywords

GAMMA GLUTAMYLTRANSFERASE;

ALCOHOL CONSUMPTION; ARTICLE; BLOOD PRESSURE; BLOOD SAMPLING; BODY MASS; DISEASE ASSOCIATION; ENZYME ACTIVITY; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; RISK ASSESSMENT; RISK FACTOR; SMOKING; SYSTEMATIC REVIEW; ADULT; AGED; BLOOD; FEMALE; MALE; META ANALYSIS; MIDDLE AGED; SEX DIFFERENCE;

ADULT; AGED; DIABETES MELLITUS, TYPE 2; FEMALE; GAMMA-GLUTAMYLTRANSFERASE; HUMANS; MALE; MIDDLE AGED; RISK FACTORS; SEX FACTORS;

EID: 84908270441     PISSN: 10472797     EISSN: 18732585     Source Type: Journal    
DOI: 10.1016/j.annepidem.2014.09.001     Document Type: Article

References (47)

1. Jung C.H., Lee M.J., Kang Y.M., Hwang J.Y., Jang J.E., Leem J., et al. Higher serum bilirubin level as a protective factor for the development of diabetes in healthy Korean men: a 4 year retrospective longitudinal study. Metabolism 2014, 63:87-93.
2. Wild S., Roglic G., Green A., Sicree R., King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004, 27:1047-1053.
3. Kahn H.S., Cheng Y.J., Thompson T.J., Imperatore G., Gregg E.W. Two risk-scoring systems for predicting incident diabetes mellitus in U.S. adults age 45 to 64 years. Ann Intern Med 2009, 150:741-751.
4. Wilson P.W., Meigs J.B., Sullivan L., Fox C.S., Nathan D.M., D'Agostino R.B. Prediction of incident diabetes mellitus in middle-aged adults: the Framingham Offspring Study. Arch Intern Med 2007, 167:1068-1074.
5. Griffin S.J., Little P.S., Hales C.N., Kinmoth A.L., Wareham N.J. Diabetes risk score: towards earlier detection of type 2 diabetes in general practice. Diabetes Metab Res Rev 2000, 16:164-171.
6. Ford E.S., Schulze M.B., Bergmann M.M., Thamer C., Joost H.G., Boeing H. Liver enzymes and incident diabetes: findings from the European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. Diabetes Care 2008, 31:1138-1143.
7. Schneider A.L., Lazo M., Ndumele C.E., Pankow J.S., Coresh J., Clark J.M., et al. Liver enzymes, race, gender and diabetes risk: the Atherosclerosis Risk in Communities (ARIC) Study. Diabet Med 2013, 30:926-933.
8. Abbasi A., Bakker S.J., Corpeleijn E., van der A D.L., Gansevoort R.T., Gans R.O., et al. Liver function tests and risk prediction of incident type 2 diabetes: evaluation in two independent cohorts. PLoS One 2012, 7:e51496.
9. Fraser A., Harris R., Sattar N., Ebrahim S., Davey Smith G., Lawlor D.A. Alanine aminotransferase, gamma-glutamyl transferase, and incident diabetes: the British Women's Heart and Health Study and meta-analysis. Diabetes Care 2009, 32:741-750.
10. Doi Y., Kubo M., Yonemoto K., Ninomiya T., Iwase M., Tanizaki Y., et al. Liver enzymes as a predictor for incident diabetes in a Japanese population: the Hisayama study. Obesity (Silver Spring) 2007, 15:1841-1850.
11. Lee D.H., Ha M.H., Kim J.H., Christiani D.C., Gross M.D., Steffes M., et al. Gamma-glutamyl transferase and diabetes-a 4 year follow-up study. Diabetologia 2003, 46:359-364.
12. Moher D., Liberati A., Tetzlaff J., Altman D.G. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009, 6:e1000097.
13. Stroup D.F., Berlin J.A., Morton S.C., Olkin I., Williamson G.D., Rennie D., et al. Meta-analysis of observational studies in epidemiology. JAMA 2000, 283:2008-2012.
14. Wells GA, Shea B, O'Connell D, J. Peterson, V. Welch, M. Losos, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2011. [assessed 05 July, cited 20 August]; http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.
15. Orsini N., Bellocco R., Greenland S. Generalized least squares for trend estimation of summarized dose-response data. Stata J 2006, 6:40-57.
16. Harrell F.E., Lee K.L., Pollock B.G. Regression models in clinical studies: determining relationships between predictors and response. JNatl Cancer Inst 1988, 80:1198-1202.
17. Chêne G., Thompson S.G. Methods for summarizing the risk associations of quantitative variables in epidemiologic studies in a consistent form. Am J Epidemiol 1996, 144:610-621.
18. Greenland S., Longnecker M.P. Methods for trend estimation from summarized dose-response data, with applications to meta-analysis. Am J Epidemiol 1992, 135:1301-1309.
19. DerSimonian R., Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986, 7:177-188.
20. Higgins J.P., Thompson S.G., Deeks J.J., Altman D.G. Measuring inconsistency in meta-analyses. BMJ 2003, 327:557-560.
21. Higgins J.P., Thompson S.G. Quantifying heterogeneity in a meta-analysis. Stat Med 2002, 21:1539-1558.
22. Thompson S.G., Sharp S.J. Explaining heterogeneity in meta-analysis: a comparison of methods. Stat Med 1999, 18:2693-2708.
23. Begg C.B., Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994, 50:1088-1101.
24. Egger M., Davey Smith G., Schneider M., Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997, 315:629-634.
25. Duval S., Tweedie R. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 2000, 56:455-463.
26. Logue J., Walker J.J., Colhoun H.M., Leese G.P., Lindsay R.S., McKnight J.A., et al. Do men develop type 2 diabetes at lower body mass indices than women?. Diabetologia 2011, 54:3003-3006.
27. Fall T., Hagg S., Magi R., Ploner A., Fischer K., Horikoshi M., et al. The role of adiposity in cardiometabolic traits: a mendelian randomization analysis,. PLoS Med 2013, 10:e1001474.
28. Franzini M., Paolicchi A., Fornaciari I., Ottaviano V., Fierabracci V., Maltinti M., et al. Cardiovascular risk factors and gamma-glutamyl transferase fractions in healthy individuals. Clin Chem Lab Med 2010, 48:713-717.
29. Franzini M., Ottaviano V., Fierabracci V., Bramanti E., Zyw L., Barsacchi R., et al. Fractions of plasma gamma-glutamyl transferase in healthy individuals: reference values. Clin Chim Acta 2008, 395:188-189.
30. Franzini M., Fornaciari I., Rong J., Larson M.G., Passino C., Emdin M., et al. Correlates and reference limits of plasma gamma-glutamyl transferase fractions from the Framingham Heart Study. Clin Chim Acta 2013, 417:19-25.
31. Kim C.H., Park J.Y., Lee K.U., Kim J.H., Kim H.K. Association of serum gamma-glutamyl transferase and alanine aminotransferase activities with risk of type 2 diabetes mellitus independent of fatty liver. Diabetes Metab Res Rev 2009, 25:64-69.
32. Wannamethee S.G., Shaper A.G., Lennon L., Whincup P.H. Hepatic enzymes, the metabolic syndrome, and the risk of type 2 diabetes in older men. Diabetes Care 2005, 28:2913-2918.
33. Lee D.H., Jacobs D.R. Association between serum gamma-glutamyl transferase and C-reactive protein. Atherosclerosis 2005, 178:327-330.
34. Robins J.M., Greenland S. Identifiability and exchangeability for direct and indirect effects. Epidemiology 1992, 3:143-155.
35. Ceriello A., Motz E. Is oxidative stress the pathogenic mechanism underlying insulin resistance, diabetes, and cardiovascular disease? The common soil hypothesis revisited. Arterioscler Thromb Vasc Biol 2004, 24:816-823.
36. Hotamisligil G.S. Inflammatory pathways and insulin action. Int J Obes Relat Metab Disord 2003, 27 Suppl 3:S53-S55.
37. Ruttmann E., Brant L.J., Concin H., Diem G., Rapp K., Ulmer H. Gamma-glutamyl transferase as a risk factor for cardiovascular disease mortality: an epidemiological investigation in a cohort of 163,944 Austrian adults. Circulation 2005, 112:2130-2137.
38. Lee D.S., Evans J.C., Robins S.J., Wilson P.W., Albano I., Fox C.S., et al. Gamma glutamyl transferase and metabolic syndrome, cardiovascular disease, and mortality risk: the Framingham Heart Study. Arterioscler Thromb Vasc Biol 2007, 27:,127-133.
39. Shield K.D., Gmel G., Kehoe-Chan T., Dawson D.A., Grant B.F., Rehm J. Mortality and potential years of life lost attributable to alcohol consumption by race and sex in the United States in 2005. PLoS One 2013, 8:e51923.
40. Whitfield J.B. Gamma glutamyl transferase. Crit Rev Clin Lab Sci 2001, 38:263-355.
41. Gunter E.W., Lewis B.G., Koncikowski S.M. Laboratory procedures used for the Third National Health and Nutrition Examination Survey (NHANES III), 1988-1994 1996, US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Environmental Health, National Center for Health Statistics, Hyattsville, MD.
42. Chitturi S., Abeygunasekera S., Farrell G.C., Holmes-Walker J., Hui J.M., Fung C., et al. NASH and insulin resistance: insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology 2002, 35:373-379.
43. Stefan N., Kantartzis K., Haring H.U. Causes and metabolic consequences of fatty liver. Endocr Rev 2008, 29:939-960.
44. Ghouri N., Preiss D., Sattar N. Liver enzymes, nonalcoholic fatty liver disease, and incident cardiovascular disease: a narrative review and clinical perspective of prospective data. Hepatology 2010, 52:1156-1161.
45. Raynor L.A., Pankow J.S., Duncan B.B., Schmidt M.I., Hoogeveen R.C., Pereira M.A., et al. Novel risk factors and the prediction of type 2 diabetes in the Atherosclerosis Risk in Communities (ARIC) study. Diabetes Care 2013, 36:70-76.
46. Marques-Vidal P., Schmid R., Bochud M., Bastardot F., von Känel R., Paccaud F., et al. Adipocytokines, hepatic and inflammatory biomarkers and incidence of type 2 diabetes. the CoLaus study. PLoS One 2012, 7:e51768.
47. Simmons R.K., Echouffo-Tcheugui J.B., Griffin S.J. Screening for type 2 diabetes: an update of the evidence. Diabetes Obes Metab 2010, 12:838-844.